Profarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 333,036 | 460,386 | 5,482,943 | 738,807 | 635,377 | 1,905,815 | 1,262,522 | 2,002,311 |
| Profit before tax | 24,857 | 47,081 | 111,781 | 194,889 | 4,764 | 453,074 | 16,378 | 12,676 |
| Net profit | 24,857 | 47,081 | 111,781 | 194,889 | 4,764 | 453,074 | 16,378 | 12,676 |
| Equity | 78,309 | 95,667 | 206,137 | 401,026 | 405,790 | 858,864 | 864,834 | 877,510 |
| Liabilities | 728,262 | 972,976 | 1,277,291 | 1,160,795 | 1,240,520 | 1,025,870 | 1,209,497 | 1,506,854 |
| Non-current assets | 589,733 | 539,136 | 504,511 | 459,370 | 619,518 | 970,094 | 787,919 | 592,323 |
| Current assets | 585,901 | 854,902 | 1,275,446 | 1,421,984 | 1,315,785 | 1,341,078 | 1,288,164 | 1,501,056 |
| Total assets | 1,175,634 | 1,394,038 | 1,779,957 | 1,881,354 | 1,935,303 | 2,311,172 | 2,076,083 | 2,093,379 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 81,027 | 32,874 | 152,308 |
| Social insurance contributions | - | - | - | - | - | 121,851 | 187,208 | 302,301 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -39.0% | +38.2% | +1090.9% | -86.5% | -14.0% | +200.0% | -33.8% | +58.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 2.1% | 3.4% | 6.3% | 10.4% | 0.2% | 19.6% | 0.8% | 0.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 31.7% | 49.2% | 54.2% | 48.6% | 1.2% | 52.8% | 1.9% | 1.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 7.5% | 10.2% | 2.0% | 26.4% | 0.7% | 23.8% | 1.3% | 0.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 7.5% | 10.2% | 2.0% | 26.4% | 0.7% | 23.8% | 1.3% | 0.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 9.3 | 10.2 | 6.2 | 2.9 | 3.1 | 1.2 | 1.4 | 1.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 18,763 | 24,554 | 310,355 | 43,247 | 34,038 | 96,092 | 50,333 | 60,069 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Profarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-06-17 | 2025-06-17 | 23040.33 |
| 2024-05-16 | 2024-05-16 | 12695.71 |
| 2022-03-16 | 2022-04-13 | 104.78 |
| 2021-12-17 | 2021-12-19 | 185.92 |
| 2021-12-16 | 2021-12-16 | 185.93 |
| 2021-12-10 | 2021-12-14 | 1044.03 |
Profarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Profarma, UAB (code 300868786) is a Private Limited Liability Company engaged in research and development in medical sciences. In 2025, the company generated revenue of EUR 2.00 million and net profit of EUR 12.7 thousand, resulting in a profit margin of 0.6%. Revenue increased by 58.6% year on year, while the two-year change was +5.1%, reflecting a recovery after the weaker 2024 result. The 2023–2025 trajectory shows revenue moving from EUR 1.91 million in 2023 to EUR 1.26 million in 2024 and then back to EUR 2.00 million in 2025. Net profit followed a much sharper decline, from EUR 453.1 thousand in 2023 to EUR 16.4 thousand in 2024 and EUR 12.7 thousand in 2025. At year-end 2025, total assets were EUR 2.09 million, equity EUR 877.5 thousand and liabilities EUR 1.51 million. Key ratios indicate moderate leverage and limited profitability, with equity ratio at 41.9%, debt-to-equity at 1.72, ROE at 1.4% and ROA at 0.6%. Revenue per employee was EUR 60.7 thousand.